Default Hero Image

Daniel M Lipinski MSc DPhil

Dan Lipinski, MSc, DPhil

Daniel Lipinski, MSc, DPhil

Assistant Professor of Ophthalmology and Visual Sciences, Assistant Professor of Cell Biology, Neurobiology and Anatomy

Locations

  • Medical College of Wisconsin Eye Institute
  • 925 N. 87th St. Room Room 722
    Milwaukee WI, 53226

Contact Information

Biography

Education

BSc, Biology, Imperial College London, UK
MSc, Virology, Imperial College London, UK
DPhil, Ophthalmology, University of Oxford, UK

Research Interests

Ocular Gene Therapy Lab

Research Interests

  • Recombinant adeno-associated virus (rAAV)-mediated gene therapy
  • Diabetic retinopathy
  • Inherited retinal disease (e.g., Retinitis pigmentosa)
  • Age-related macular degeneration (AMD) 

Research Team

 

Research Summary

The overarching theme of my research program is the development of broadly applicable gene-based therapeutics to preserve vision in neurodegenerative and vascular diseases affecting the retina. Toward this end, the Lipinski research group focuses on a number of key areas:

1) The development of recombinant adeno-associated virus (rAAV)-mediated gene therapies to prevent cone photoreceptor degeneration in end-stage retinitis pigmentosa. 

2) Developing gene therapy approaches to target the retinal and choroidal vasculature in diabetic retinopathy and age-related macular degeneration.

3) Restoration of light sensitivity/vision in the totally degenerate retina.

Funding for this research: Department of Ophthalmology Special Endowment (PI: Lipinski DM)
Past grant support/funding: Juvenile Diabetes Research Foundation (JDRF) Innovative Grant (2014-2015, PI: Lipinski DM); Fulbright-Fight for Sight (UK) Research Scholarship (2013-2015, PI: Lipinski DM); Fight for Sight (UK) PhD Studentship (2009-2012, PI: MacLaren RE)

Publications

Ocular Gene Therapy

 The Ocular Gene Therapy Laboratory (OGTL), founded by Daniel M. Lipinski, MSc, DPhil, and located in the Eye Institute, aims to develop broadly applicable gene-based therapeutics to prevent human blindness arising from neurodegenerative or vascular diseases affecting the retina. More information about this lab is available on the OGTL Website
 

OGT_Square_White